ALX Oncology disclosed that its Phase 2 investigator‑sponsored study of evorpacept, combined with rituximab and lenalidomide, achieved a 92% complete‑response rate in 24 patients with untreated indolent B‑cell non‑Hodgkin lymphoma. The trial reported a 100% overall‑response rate, with 8% partial responses, and a one‑year progression‑free survival of 91%. One‑year overall survival was 100%, and the combination was well tolerated with no new safety signals.
The 92% complete‑response rate far exceeds the approximately 50% historical complete‑response rate for the rituximab‑lenalidomide (R2) regimen in this disease setting, suggesting that evorpacept’s CD47 blockade markedly enhances the efficacy of rituximab. The data also confirm that the “dead Fc” design of evorpacept, which eliminates Fc‑mediated effector functions, does not compromise safety while enabling robust antibody‑dependent cellular phagocytosis.
Evorpacept blocks the CD47 protein, a “don’t‑eat‑me” signal that is overexpressed on many lymphoma cells. By inhibiting CD47, evorpacept exposes malignant cells to macrophage‑mediated clearance, amplifying the therapeutic effect of rituximab. The trial’s success in a frontline population demonstrates that this mechanism translates into durable remissions in real‑world patients.
CEO Jason Lettmann said the results “add a meaningful benefit over the historical data for the standard‑of‑care R2 regimen.” He noted that the study confirms the activity seen in earlier relapsed‑refractory trials and underscores the potential of evorpacept as a cornerstone therapy in immuno‑oncology.
ALX’s cash balance of $67 million is expected to fund operations through the first quarter of 2027, giving the company runway to pursue further development and regulatory milestones. While no regulatory approval has yet been granted, the data position evorpacept favorably against competitors in the CD47 space, where no agents have received approval and several programs have faced setbacks.
Although specific market‑reaction data are not available, the strong clinical outcomes are likely to influence investor sentiment and analyst coverage, as the results provide a clear signal of therapeutic potential and a possible pathway to market approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.